JP2012140442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012140442A5 JP2012140442A5 JP2012036919A JP2012036919A JP2012140442A5 JP 2012140442 A5 JP2012140442 A5 JP 2012140442A5 JP 2012036919 A JP2012036919 A JP 2012036919A JP 2012036919 A JP2012036919 A JP 2012036919A JP 2012140442 A5 JP2012140442 A5 JP 2012140442A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- pathway
- dna
- treated
- initial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (2)
- 治療すべきガン細胞におけるDNA−PK経路の、少なくとも1つの構成タンパク質の始めの量を測定すること、及び該始めの量と2回目の量とを比較することを含む方法。
- 前記始めの量が治療前の量であり、前記2回目の量が治療すべきガンと同じ組織に由来する正常細胞における、DNA−PK経路の構成タンパク質の量である、請求項33記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55357804P | 2004-03-15 | 2004-03-15 | |
US60/553,578 | 2004-03-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503972A Division JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014091125A Division JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012140442A JP2012140442A (ja) | 2012-07-26 |
JP2012140442A5 true JP2012140442A5 (ja) | 2013-04-04 |
Family
ID=34993432
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Sns−595、及びその使用方法 |
JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Sns−595、及びその使用方法 |
JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Sns−595、及びその使用方法 |
JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Sns−595、及びその使用方法 |
JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Sns−595、及びその使用方法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Sns−595、及びその使用方法 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Sns−595、及びその使用方法 |
JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Sns−595、及びその使用方法 |
JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Sns−595、及びその使用方法 |
Country Status (24)
Country | Link |
---|---|
US (12) | US7968565B2 (ja) |
EP (4) | EP3053579A1 (ja) |
JP (9) | JP5096913B2 (ja) |
KR (1) | KR101169825B1 (ja) |
CN (5) | CN103083316B (ja) |
AT (2) | ATE451924T1 (ja) |
AU (3) | AU2005222607B2 (ja) |
BR (1) | BRPI0508700A (ja) |
CA (3) | CA2559652C (ja) |
CY (2) | CY1109741T1 (ja) |
DE (2) | DE602005025738D1 (ja) |
DK (3) | DK2295056T5 (ja) |
ES (3) | ES2334802T3 (ja) |
HK (1) | HK1097196A1 (ja) |
HU (1) | HUE027266T2 (ja) |
IL (2) | IL177946A (ja) |
MX (2) | MXPA06010382A (ja) |
NO (3) | NO338058B1 (ja) |
NZ (2) | NZ549557A (ja) |
PL (3) | PL1725233T3 (ja) |
PT (2) | PT1725233E (ja) |
SI (2) | SI1729770T1 (ja) |
WO (2) | WO2005089757A1 (ja) |
ZA (1) | ZA200607248B (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1725233T3 (pl) | 2004-03-15 | 2011-05-31 | Sunesis Pharmaceuticals Inc | Kompozycja farmaceutyczna zawierająca SNS-595 i jej zastosowanie |
KR100989029B1 (ko) * | 2004-09-17 | 2010-10-25 | 사일린 파마슈티칼스, 인크 | 세포 증식 억제제로서의 퀴놀론 동족체 |
US7652134B2 (en) * | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
JP2009504192A (ja) * | 2005-08-19 | 2009-02-05 | サイリーン ファーマシューティカルズ インコーポレーティッド | ヒトリボソームDNA(rDNA)およびリボソームRNA(rRNA)核酸ならびにそれらの使用 |
WO2007028171A1 (en) * | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
JP5374153B2 (ja) * | 2005-09-02 | 2013-12-25 | サネシス ファーマシューティカルズ, インコーポレイテッド | 癌の治療のための(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸を使用する方法 |
MX2008015775A (es) * | 2006-06-12 | 2009-04-17 | Sunesis Pharmaceuticals Inc | Compuestos y composiciones para tratamiento de cancer. |
US20100048609A1 (en) * | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
WO2008016702A2 (en) * | 2006-08-02 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic |
EP2209380A4 (en) * | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
AU2014277779B2 (en) * | 2007-10-22 | 2016-05-19 | Sunesis Pharmaceuticals, Inc. | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY |
CN103720701A (zh) * | 2007-10-22 | 2014-04-16 | 逊尼希思制药公司 | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 |
AU2008335772B2 (en) * | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
SG10201504789RA (en) | 2008-12-31 | 2015-07-30 | Sunesis Pharmaceuticals Inc | Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid |
EP2400959A1 (en) * | 2009-02-27 | 2012-01-04 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
TW201120037A (en) * | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
CN108551828B (zh) | 2012-02-27 | 2021-04-30 | 阿吉齐科技公司 | 土壤条件的监测与控制 |
RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
RS58374B1 (sr) | 2013-03-12 | 2019-03-29 | Vertex Pharma | Inhibitori dnk-pk |
US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
EP3057953B1 (en) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US216316A (en) * | 1879-06-10 | Improvement in latches | ||
US3021A (en) * | 1843-03-30 | Stove with elevated ovejst | ||
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
JP3391796B2 (ja) * | 1994-06-14 | 2003-03-31 | 大日本製薬株式会社 | 新規化合物、その製法および抗腫瘍剤 |
JP4323574B2 (ja) * | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
GB2322193B (en) * | 1997-01-13 | 1999-09-29 | Cancer Res Campaign Tech | Assays,agents,therapy and diagnosis relating to modulation of cellular dna repair activity |
US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
EP1003856A1 (en) * | 1997-06-05 | 2000-05-31 | Board of Regents, The University of Texas System | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
JP2002519010A (ja) * | 1998-06-30 | 2002-07-02 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | Dna−pkの使用法 |
US6670144B1 (en) * | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
MXPA01008626A (es) | 1999-02-26 | 2002-04-24 | Univ Johns Hopkins | Inhibidor novedoso de muerte programada de celula. |
US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
AU2001256530A1 (en) * | 2000-05-20 | 2001-12-03 | Cancer Research Technology Limited | Drug screening systems and assays |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
US6696483B2 (en) * | 2000-10-03 | 2004-02-24 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
CN1473055A (zh) * | 2000-11-02 | 2004-02-04 | ˹¡-�����ְ�֢�о��� | 通过使用hsp90抑制剂提高细胞毒剂效力的方法 |
WO2003089573A2 (en) * | 2002-04-05 | 2003-10-30 | Fishel Richard A | Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
CA2523178C (en) | 2003-03-24 | 2012-10-23 | Luitpold Pharmaceuticals, Inc. | Materials and methods to potentiate cancer treatment |
PL1725233T3 (pl) | 2004-03-15 | 2011-05-31 | Sunesis Pharmaceuticals Inc | Kompozycja farmaceutyczna zawierająca SNS-595 i jej zastosowanie |
US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
WO2007028171A1 (en) | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
MX2008015775A (es) * | 2006-06-12 | 2009-04-17 | Sunesis Pharmaceuticals Inc | Compuestos y composiciones para tratamiento de cancer. |
US20100048609A1 (en) | 2006-08-01 | 2010-02-25 | Jacobs Jeffrey W | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
WO2008016702A2 (en) * | 2006-08-02 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic |
CN103720701A (zh) | 2007-10-22 | 2014-04-16 | 逊尼希思制药公司 | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 |
AU2008335772B2 (en) | 2007-12-10 | 2014-11-27 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
SG10201504789RA (en) | 2008-12-31 | 2015-07-30 | Sunesis Pharmaceuticals Inc | Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid |
EP2400959A1 (en) | 2009-02-27 | 2012-01-04 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
CN101631081B (zh) | 2009-08-12 | 2011-06-08 | 华为技术有限公司 | 一种多级交换网 |
UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
TW201120037A (en) | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
-
2005
- 2005-03-14 PL PL05731600T patent/PL1725233T3/pl unknown
- 2005-03-14 CN CN201210307920.9A patent/CN103083316B/zh not_active Expired - Fee Related
- 2005-03-14 NZ NZ549557A patent/NZ549557A/en not_active IP Right Cessation
- 2005-03-14 CN CN201410477839.4A patent/CN104324029A/zh active Pending
- 2005-03-14 PL PL05732554T patent/PL1729770T3/pl unknown
- 2005-03-14 CN CN201210307785.8A patent/CN103251589B/zh not_active Expired - Fee Related
- 2005-03-14 AU AU2005222607A patent/AU2005222607B2/en not_active Ceased
- 2005-03-14 DK DK10177951.0T patent/DK2295056T5/en active
- 2005-03-14 DK DK05732554.0T patent/DK1729770T3/da active
- 2005-03-14 ZA ZA200607248A patent/ZA200607248B/xx unknown
- 2005-03-14 EP EP15202939.3A patent/EP3053579A1/en not_active Withdrawn
- 2005-03-14 EP EP05732554A patent/EP1729770B1/en not_active Not-in-force
- 2005-03-14 JP JP2007503972A patent/JP5096913B2/ja not_active Expired - Fee Related
- 2005-03-14 CN CN200910221540A patent/CN101703508A/zh active Pending
- 2005-03-14 DK DK05731600.2T patent/DK1725233T3/da active
- 2005-03-14 PT PT05731600T patent/PT1725233E/pt unknown
- 2005-03-14 MX MXPA06010382A patent/MXPA06010382A/es active IP Right Grant
- 2005-03-14 CA CA2559652A patent/CA2559652C/en not_active Expired - Fee Related
- 2005-03-14 JP JP2007503987A patent/JP5317472B2/ja not_active Expired - Fee Related
- 2005-03-14 ES ES05732554T patent/ES2334802T3/es active Active
- 2005-03-14 EP EP10177951.0A patent/EP2295056B9/en not_active Not-in-force
- 2005-03-14 CA CA2954578A patent/CA2954578A1/en not_active Abandoned
- 2005-03-14 AU AU2005222622A patent/AU2005222622B2/en not_active Ceased
- 2005-03-14 SI SI200530890T patent/SI1729770T1/sl unknown
- 2005-03-14 SI SI200531244T patent/SI1725233T1/sl unknown
- 2005-03-14 PL PL10177951T patent/PL2295056T3/pl unknown
- 2005-03-14 ES ES10177951.0T patent/ES2566973T3/es active Active
- 2005-03-14 DE DE602005025738T patent/DE602005025738D1/de active Active
- 2005-03-14 HU HUE10177951A patent/HUE027266T2/en unknown
- 2005-03-14 EP EP05731600A patent/EP1725233B1/en not_active Not-in-force
- 2005-03-14 MX MX2011011851A patent/MX349188B/es unknown
- 2005-03-14 ES ES05731600T patent/ES2358267T3/es active Active
- 2005-03-14 US US11/080,102 patent/US7968565B2/en not_active Expired - Fee Related
- 2005-03-14 WO PCT/US2005/008346 patent/WO2005089757A1/en active Application Filing
- 2005-03-14 KR KR1020067021270A patent/KR101169825B1/ko active IP Right Grant
- 2005-03-14 AT AT05732554T patent/ATE451924T1/de active
- 2005-03-14 WO PCT/US2005/008036 patent/WO2005089756A1/en active Application Filing
- 2005-03-14 BR BRPI0508700-7A patent/BRPI0508700A/pt not_active IP Right Cessation
- 2005-03-14 PT PT05732554T patent/PT1729770E/pt unknown
- 2005-03-14 US US11/080,283 patent/US7989468B2/en not_active Expired - Fee Related
- 2005-03-14 CA CA2559650A patent/CA2559650C/en not_active Expired - Fee Related
- 2005-03-14 AT AT05731600T patent/ATE493982T1/de active
- 2005-03-14 CN CN200580015456.4A patent/CN1997368B/zh not_active Expired - Fee Related
- 2005-03-14 DE DE602005018333T patent/DE602005018333D1/de active Active
- 2005-04-14 NZ NZ588060A patent/NZ588060A/en not_active IP Right Cessation
- 2005-09-02 US US11/218,387 patent/US20060025437A1/en active Pending
- 2005-09-02 US US11/218,653 patent/US20060063795A1/en active Pending
-
2006
- 2006-06-29 US US11/478,765 patent/US7829577B2/en not_active Expired - Fee Related
- 2006-09-07 IL IL177946A patent/IL177946A/en not_active IP Right Cessation
- 2006-10-12 NO NO20064647A patent/NO338058B1/no not_active IP Right Cessation
-
2007
- 2007-05-07 HK HK07104836.3A patent/HK1097196A1/xx not_active IP Right Cessation
-
2010
- 2010-01-21 CY CY20101100063T patent/CY1109741T1/el unknown
-
2011
- 2011-02-03 CY CY20111100114T patent/CY1111263T1/el unknown
- 2011-03-22 AU AU2011201277A patent/AU2011201277B2/en not_active Ceased
- 2011-04-27 US US13/095,111 patent/US20110263524A1/en not_active Abandoned
- 2011-06-13 US US13/159,258 patent/US8669270B2/en not_active Expired - Fee Related
- 2011-06-17 JP JP2011135675A patent/JP2011225590A/ja active Pending
-
2012
- 2012-02-23 JP JP2012036919A patent/JP2012140442A/ja active Pending
-
2013
- 2013-03-11 US US13/794,583 patent/US8822493B2/en not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,673 patent/US20140378505A1/en not_active Abandoned
- 2014-04-25 JP JP2014091125A patent/JP5856644B2/ja not_active Expired - Fee Related
- 2014-08-18 US US14/462,439 patent/US9980949B2/en not_active Expired - Fee Related
- 2014-09-05 JP JP2014180862A patent/JP6261477B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-17 NO NO20150466A patent/NO339613B1/no not_active IP Right Cessation
- 2015-07-14 JP JP2015140309A patent/JP6352863B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 US US14/996,025 patent/US9757363B2/en not_active Expired - Fee Related
- 2016-09-26 IL IL248049A patent/IL248049A0/en unknown
- 2016-11-24 NO NO20161867A patent/NO20161867A1/no not_active Application Discontinuation
- 2016-12-21 JP JP2016248041A patent/JP2017095471A/ja active Pending
-
2018
- 2018-03-05 JP JP2018038834A patent/JP2018119977A/ja active Pending
- 2018-04-27 US US15/965,741 patent/US20180316309A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012140442A5 (ja) | ||
EP3082840A4 (en) | Methods and assays relating to circulating tumor cells | |
EP2850675A4 (en) | ELECTROCHEMICAL CELLS AND METHODS OF MAKING THE SAME | |
WO2013006490A3 (en) | Antibodies that specifically bind to tim3 | |
EP2853597A4 (en) | NUCLEIC ACID MOLECULE INDUCING INTERFERING RNA CAPABLE OF PENETRATING IN CELLS AND USE THEREOF | |
EP3083658A4 (en) | Methods and assays relating to circulating tumor cells | |
CL2015000084A1 (es) | Célula huésped, particularmente de hongo filamentoso, deficiente en la producción de proteína agse; y método de producción de la célula. | |
EP2827842A4 (en) | CYCLODEXTRIN MICROEMULSIONS AND DERMATOLOGICAL USES THEREOF | |
CL2013000238A1 (es) | Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos. | |
JP2012144538A5 (ja) | ||
EP3063267A4 (en) | Cardiac neural crest cells and methods of use thereof | |
HK1214624A1 (zh) | 心臟幹細胞和其識別方法和用途 | |
HK1205185A1 (en) | Methods and composition related to brown adipose-like cells | |
TR201911039T4 (tr) | Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler. | |
EP2807209A4 (de) | Kompositmaterial, dessen herstellung und dessen verwendung in separatoren für elektrochemische zellen | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
DK2920282T3 (da) | Alkylenkoblede phenoler til anvendelse i biodieselmotorer | |
PL2853849T3 (pl) | Pomieszczenie suche, zwłaszcza do zastosowania w produkcji ogniw litowo-jonowych | |
EP3094956A4 (en) | Preparation of cells, cell aggregates, and tissue fragments | |
IL232642A0 (en) | A method for characterizing circulating cells and its use in diagnosis | |
PT2859092T (pt) | ¿vacina terapêutica para tratamento de diabetes tipo 1 em crianças, aplicação do separador de células e método de multiplicação de células treg para produzir a vacina terapêutica para tratamento de diabetes tipo 1¿ | |
EP2845898A4 (en) | METHOD FOR CULTIVATING NEURAL CREST STEM CELLS, AND USE THEREOF | |
CO6801702A2 (es) | El uso de la vinaza en el proceso de sacrificación de la biomasa lignocelulósica | |
WO2012068038A3 (en) | Caffeic acid derivatives and their use in improving neuronal cell viability | |
EP2826085A4 (de) | Kompositmaterialien, ihre herstellung und verwendung in elektrochemischen zellen |